Precision BioSciences Announces In Vivo Gene Editing Collaboration with Novartis to Develop Potentially Curative Treatment for Disorders Including Sickle Cell Disease

Source :: Plus Company Updates. June 22, 2022
Publication Year :: 2022
Abstract: DURHAM: PRECISION BIOSCIENCES, INC. has issued the following news release: Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in [...]

Subjects :: Novartis Pharma AG -- Licensing agreements
Sickle cell anemia
Genes
Biotechnology industry -- Licensing agreements
Industrial research -- Switzerland
Pharmaceutical industry -- Licensing agreements
Research and development
Company licensing agreement
General interest
News, opinion and commentary

Tools